These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

394 related articles for article (PubMed ID: 22305032)

  • 1. Mechanisms of resistance and clinical relevance of resistance to β-lactams, glycopeptides, and fluoroquinolones.
    Rice LB
    Mayo Clin Proc; 2012 Feb; 87(2):198-208. PubMed ID: 22305032
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationships between antimicrobial use and antimicrobial resistance in Gram-negative bacteria causing nosocomial infections from 1991-2003 at a university hospital in Taiwan.
    Hsueh PR; Chen WH; Luh KT
    Int J Antimicrob Agents; 2005 Dec; 26(6):463-72. PubMed ID: 16280243
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms of resistance to beta-lactams in some common Gram-negative bacteria causing nosocomial infections.
    Suárez CJ; Lolans K; Villegas MV; Quinn JP
    Expert Rev Anti Infect Ther; 2005 Dec; 3(6):915-22. PubMed ID: 16307504
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An update on the management of urinary tract infections in the era of antimicrobial resistance.
    Bader MS; Loeb M; Brooks AA
    Postgrad Med; 2017 Mar; 129(2):242-258. PubMed ID: 27712137
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel Antibiotics in the Treatment of Urinary Tract Infections.
    Naber KG; Wagenlehner FME
    Eur Urol Focus; 2019 Jan; 5(1):10-12. PubMed ID: 30555037
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [News of antibiotic resistance among Gram-negative bacilli in Algeria].
    Baba Ahmed-Kazi Tani Z; Arlet G
    Pathol Biol (Paris); 2014 Jun; 62(3):169-78. PubMed ID: 24819127
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Antimicrobial susceptibility and molecular mechanisms of resistance to beta-lactams of gram-negative microorganisms--causative agents of nosocomial infections].
    Krapivina IV; Galeeva EV; Veshutova NS; Ivanov DV; Sidorenko SV
    Zh Mikrobiol Epidemiol Immunobiol; 2007; (5):16-20. PubMed ID: 18038541
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Detection of resistance phenotypes in gram-negative bacteria].
    Navarro F; Calvo J; Cantón R; Fernández-Cuenca F; Mirelis B
    Enferm Infecc Microbiol Clin; 2011; 29(7):524-34. PubMed ID: 21696863
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Forthcoming therapeutic perspectives for infections due to multidrug-resistant Gram-positive pathogens.
    Cornaglia G; Rossolini GM
    Clin Microbiol Infect; 2009 Mar; 15(3):218-23. PubMed ID: 19335369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. β-Lactam and glycopeptide antibiotics: first and last line of defense?
    Jovetic S; Zhu Y; Marcone GL; Marinelli F; Tramper J
    Trends Biotechnol; 2010 Dec; 28(12):596-604. PubMed ID: 20970210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The growing problem of antibiotic resistance in clinically relevant Gram-negative bacteria: current situation].
    Martínez-Martínez L; Calvo J
    Enferm Infecc Microbiol Clin; 2010 Sep; 28 Suppl 2():25-31. PubMed ID: 21130927
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative antimicrobial susceptibility of aerobic and facultative bacteria from community-acquired bacteremia to ertapenem in Taiwan.
    Lee SC; Huang SS; Lee CW; Fung CP; Lee N; Shieh WB; Siu LK
    BMC Infect Dis; 2007 Jul; 7():79. PubMed ID: 17640342
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Broad-spectrum beta-lactamases in Gram-negative bacteria].
    Sundsfjord A; Simonsen GS; Haldorsen B; Lundblad EW; Samuelsen O
    Tidsskr Nor Laegeforen; 2008 Dec; 128(23):2741-5. PubMed ID: 19079424
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms of the resistance and tolerance to beta-lactam and glycopeptide antibiotics in pathogenic gram-positive cocci.
    Mlynarczyk A; Mlynarczyk B; Kmera-Muszynska M; Majewski S; Mlynarczyk G
    Mini Rev Med Chem; 2009 Nov; 9(13):1527-37. PubMed ID: 20205634
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of an infectious diseases specialist-led antimicrobial stewardship programmes on antibiotic use and antimicrobial resistance in a large Korean hospital.
    Hwang H; Kim B
    Sci Rep; 2018 Oct; 8(1):14757. PubMed ID: 30283084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Addressing the challenge of extended-spectrum beta-lactamases.
    Zahar JR; Lortholary O; Martin C; Potel G; Plesiat P; Nordmann P
    Curr Opin Investig Drugs; 2009 Feb; 10(2):172-80. PubMed ID: 19197795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dalbavancin: an investigational glycopeptide.
    Guay DR
    Expert Rev Anti Infect Ther; 2004 Dec; 2(6):845-52. PubMed ID: 15566329
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antimicrobial susceptibility trends and evolution of isolates with extended spectrum β-lactamases among Gram-negative organisms recovered during the SMART study in Spain (2011-2015).
    Cantón R; Loza E; Aznar J; Barrón-Adúriz R; Calvo J; Castillo FJ; Cercenado E; Cisterna R; González-Romo F; López-Hontangas JL; Suárez-Barrenechea AI; Tubau F; Molloy B; López-Mendoza D;
    Rev Esp Quimioter; 2018 Apr; 31(2):136-145. PubMed ID: 29532655
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antimicrobial resistance in Europe and its potential impact on empirical therapy.
    Rossolini GM; Mantengoli E
    Clin Microbiol Infect; 2008 Dec; 14 Suppl 6():2-8. PubMed ID: 19040461
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resistance in nonfermenting gram-negative bacteria: multidrug resistance to the maximum.
    McGowan JE
    Am J Med; 2006 Jun; 119(6 Suppl 1):S29-36; discussion S62-70. PubMed ID: 16735148
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.